• Cancel
    Date：2018-11
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=404

    On November 7, 2018, in Beijing, AI medical imaging leader, HuiyiHuiying, announced that it received investments from Intel Capital and Beijing Kinetic Energy Investment Fund, completing a strategic round of investment. The funds will be used for the comp

  • Cancel
    Date：2018-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=406

    Pioneer of the 3D printed pharmaceutical industry, Nanjing Triastek Pharmaceutical Technology Co., Ltd. (also known as “Triastek”), recently raised RMB 100 million, completing its A round of financing. The lead investor was Morningside Venture Capital and the follow investors were Volcanics Ventures and InnoVision Capital. CEC Capital served as the sole financial adviser to CMLabs during this round of financing.

  • Cancel
    Date：2018-05
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=405

    Leading third-party medical testing service provider, Chain Medical Labs (CMLabs), recently announced that it raised hundreds of millions of RMB and the completed its latest B round of financing. The co-lead investors were C-Bridge Capital and Huatai Ruih

  • Cancel
    Date：2018-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=369

    Innovative Cellular Therapeutics (ICT) announced that the company had completed its Series B financing of RMB 180 million. Investors in this new round included Volcanics Venture, GTJA Investment Group, SBCVC, Dunhou Capital and Withtruth Capital. The com

  • Cancel
    Date：2018-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=352

    EYEGOOD OPHTHALMIC, chain brand of domestic leading ophthalmic hospital, announced that the company has completed $40 million series B financing led by CDH Investments. This is a new round of financing after series A by OrbiMed in 2015.

  • Cancel
    Date：2017-11
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=327

    3D Medicines, Chinese leading cancer-targeted theranostic platform company, has raised ¥670 million in a new funding round recently. The round was led by the State-Controlled Venture Capital Fund mainly sponsored by China Reform Holdings Corporation LTD.

  • Cancel
    Date：2017-11
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=325

    Zensun Sci & Tech (871392.OC), a leading innovative drug developer in China, announced an impressive RMB 507 million financing round yesterday, led by SDIC Venture Capital Management Co., Ltd., with a host of new backers including Tianfeng Tianrui Investm

  • Cancel
    Date：2017-11
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=324

    Cygnus Biosciences (Beijing) Co., Ltd., a leading domestic company focusing on developing local High-Throughput DNA sequencing platform, announced its Series B financing of RMB 130 million which was jointly led by Oriental Yirui (Shanghai) Fund and the Zh

  • Cancel
    Date：2017-09

    CEC Capital Served as Exclusive Financial Advisor